Gyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics (Nasdaq: GYRE) reported Q2 2026 revenue of $29.1 million and GAAP basic EPS of $(0.12). Full-year 2026 revenue guidance of $100.5 to $111.0 million was affirmed. The company said China’s CDE accepted its F351 NDA for CHB-induced liver fibrosis in May 2026 and noted Q2 sales growth for ETUARY.
How this was made
The 30-second read
Why it matters
Traders can update valuation drivers around (1) affirmed 2026 revenue guidance, (2) incremental regulatory probability for F351 after CDE NDA acceptance, and (3) pipeline expansion from Cullgen that may affect future milestone expectations.
Market read
This is a company-specific catalyst bundle: Q2 financials plus affirmed full-year guidance, and a concrete China regulatory acceptance for F351 that can shift approval probability and risk premium.
What to watch
Cash decreased year-to-date and collaboration revenue fell after the Astellas agreement ended in March 2026, which could pressure near-term expectations despite ETUARY growth.
Background
Gyre is a commercial-stage biopharma with products in China and a pipeline spanning fibrosis and, via the Cullgen acquisition, targeted protein degraders for oncology and inflammatory diseases.
Ticker impact
Gyre reported Q2 2026 results, affirmed 2026 revenue guidance, and said China’s CDE accepted its F351 NDA for CHB-induced liver fibrosis.
Bias modestly positive, with volatility likely around any follow-on NMPA review milestones and continued ETUARY sales trajectory.
The article contains multiple primary disclosures: Q2 financials, affirmed guidance, and a specific NMPA/CDE NDA acceptance event, which can re-rate probability of future approvals. However, it does not provide new Phase 3 efficacy data or a definitive approval timeline.
Market effects
Adds another China regulatory milestone for a commercial-stage fibrosis franchise, supporting sentiment toward China biopharma development pipelines.
China NMPA/CDE acceptance can improve perceived regulatory throughput for PRC-submitted NDAs in liver fibrosis.
Cullgen acquisition expands targeted protein degrader exposure, which can influence broader investor appetite for next-gen oncology and inflammatory modalities.
Counterpoint
NDA acceptance is not approval; without updated clinical efficacy or a clear review timeline, the market may fade the initial regulatory optimism.
Key entities
- companyGyre Therapeutics, Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 results, affirming 2026 revenue guidance, and updating its F351 NDA status in China.
- drug_programF351 (hydronidone)
China NDA accepted by CDE for CHB-induced liver fibrosis, following priority review status granted in March 2026.
- acquisition_targetCullgen Inc.
Acquired in an all-stock transaction valued at about $300 million; brought degrader pipeline assets and leadership changes.
- commercial_productETUARYTM (pirfenidone)
Primary China-approved product for IPF; Q2 2026 sales rose to $28.0 million from $23.5 million a year earlier.
- regulatorNMPA/CDE
China’s National Medical Products Administration and its Center for Drug Evaluation accepted Gyre’s F351 NDA in May 2026.
